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A B S T R A C T
Background
Preterm birth is the leading cause of death and disability in newborns worldwide. A wide variety of tocolytic agents have been utilized
to delay birth for women in preterm labor. One of the earliest tocolytics utilized for this purpose was ethanol infusion, although this is
not generally used in current practice due to safety concerns for both the mother and her baby.
Objectives
To determine the efficacy of ethanol in stopping preterm labor, preventing preterm birth, and the impact of ethanol on neonatal
outcomes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (31 May 2015) and reference lists of retrieved studies.
Selection criteria
We included randomized and quasi-randomized studies. Cluster-randomized trials and cross-over design trials were not eligible for
inclusion. We only included studies published in abstract form if there was enough information on methods and relevant outcomes.
Trials were included if they compared ethanol infusion to stop preterm labor versus placebo/control or versus other tocolytic drugs.
Data collection and analysis
At least two review authors independently assessed studies for inclusion and risk of bias. At least two review authors independently
extracted data. Data were checked for accuracy.
Main results
Twelve trials involving 1586 women met inclusion criteria for this review. One trial did not report on the outcomes of interest in this
review.
Risk of bias of included studies: The included studies generally were of low quality based on inadequate reporting of methodology.
Only three trials had low risk of bias for random sequence generation and one had low risk of bias for allocation concealment and
participant blinding. Most studies were either high risk of bias or uncertain in these key areas.
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Comparison 1: Ethanol versus placebo/control (two trials, 77 women)
Compared to controls receiving pain medications and dextrose solution, ethanol did not improve any of the primary outcomes: birth
< 48 hours after trial entry (one trial, 35 women; risk ratio (RR) 0.93, 95% confidence interval (CI) 0.43 to 2.00), or neonatal
mortality (one trial, 35 women; RR 1.06, 95% CI 0.31 to 3.58). Serious maternal adverse events and perinatal mortality were not
reported by either of the two trials in this comparison. Maternal adverse events (overall) were not reported but one trial (42 women)
reported that there were no maternal adverse events that required stopping or changing drug) in either group. One trial did report delay
until delivery but this outcome was reported as a median with no mention of the standard deviation (median 19 days in ethanol group
versus “less than 1” day in the glucose/water group). There were no differences in any secondary outcomes reported: preterm birth <
34 weeks or < 37 weeks; serious infant outcome; fetal alcohol syndrome/fetal alcohol spectrum disorder; or small-for-gestational age.
Comparison 2: Ethanol versus other tocolytic (betamimetics) (nine trials, 1438 women)
Compared to betamimetics (the only tocolytic used as a comparator in these studies), ethanol was associated with no clear difference
in the rate of birth < 48 hours after trial entry (two trials, 130 women; average RR 1.12, 95% CI 0.53 to 2.37, Tau² = 0.19, I² =
59%), similar rates of perinatal mortality (six trials, 698 women; RR1.20, 95% CI 0.78 to 1.84), higher rates of neonatal mortality
(eight trials, 1238 women; RR 1.43, 95% CI 1.02 to 2.02), higher rates of preterm birth < 34 weeks (two trials, 599 women; RR 1.56,
95% CI 1.11 to 2.19), higher rates of neonatal respiratory distress syndrome (three trials, 823 women; RR 1.76, 95% CI 1.33 to 2.33),
and higher rates of low birthweight babies < 2500 g (five trials, 834 women; RR 1.30, 95% CI 1.09 to 1.54). These outcomes are
likely all related to the lower incidence of preterm birth seen with other tocolytics, which for all these comparisons were betamimetics.
Serious maternal adverse events were not reported in any of the nine trial reports. However, ethanol had a trend towards a lower rate
of maternal adverse events requiring stopping or changing the drug (three trials, 214 women; RR 0.25, 95% CI 0.06 to 0.97). There
were no differences in other secondary outcomes of preterm birth < 37 weeks, number of days delivery was delayed, or overall maternal
adverse events.
Planned sensitivity analysis, excluding quasi-randomized trials did not substantially change the results of the primary outcome analyses
with the exception of neonatal mortality which no longer showed a clear difference between the ethanol and other tocolytic groups (3
trials, 330 women; RR 1.49, 95% CI 0.82 to 2.72).
Authors’ conclusions
This review is based on evidence from twelve studies which were mostly low quality. There is no evidence that to suggest that ethanol
is an effective tocolytic compared to placebo. There is some evidence that ethanol may be better tolerated than other tocolytics (in
this case betamimetics), but this result is based on few studies and small sample size and therefore should be interpreted with caution.
Ethanol appears to be inferior to betamimetics for preventing preterm birth in threatened preterm labor.
Ethanol is generally no longer used in current practice due to safety concerns for themother and her baby. There is no need for new studies
to evaluate the use of ethanol for preventing preterm birth in threatened preterm labour. However, it would be useful for long-term
follow-up studies on the babies born to mothers from the existing studies in order to assess the risk of long-term neurodevelopmental
status.
P L A I N L A N G U A G E S U M M A R Y
Ethanol (alcohol) for preventing preterm birth
Preterm birth is when a baby is born at less than 37 weeks’ gestation. These babies are generally more ill and are less likely to survive
than babies born at term. Preterm babies are also more likely to have some disability, and the earlier the baby is born the more likely
they are to have problems. Even short-term postponement of preterm birth can improve outcomes for babies, as this gives time for the
mother to be given a steroid injection to help develop the baby’s lungs prior to birth. Short-term postponement of preterm birth may
also give the chance to transfer the mother, if required, to somewhere where there is more expert care for the baby available.
Drugs used to try and stop labor are called tocolytics. These drugs are given to women experiencing preterm labor to try and stop or
relax uterine contractions. One of the earliest drugs used to try and stop contractions was ethanol (also known as alcohol), although
this is not generally used in current practice due to safety concerns for both the mother and her baby. In this review, we looked at the
published studies to see if ethanol was effective in postponing labor and improving outcomes for babies, and also whether ethanol was
better than other types of tocolytics used to postpone preterm labor and birth.
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We searched for trials evidence on 31 May 2015 and found 12 trials total involving 1586 women, some comparing ethanol with a
placebo and others comparing ethanol with other tocolytics (in this instance, all betamimetics). The trials included in this review were
considered to be mostly low quality studies.
For our comparison of ethanol versus placebo control (two trials, 77 women). We found that ethanol was no better than placebo (sugar
water) for any of the outcomes studied: birth <48 hours after trial entry (one trial, 35 women) or neonatal mortality (one trial, 35
women). Serious maternal adverse events and perinatal mortality was not reported. There was no differences between groups for other
outcomes: preterm birth < 37 weeks or < 34 weeks, serious infant outcome, fetal alcohol syndrome/fetal alcohol spectrum disorder, or
small-for-gestational age.
We also compared ethanol with other tocolytic drugs (nine trials involving 1438 women; all trials studied betamimetic drugs). We
found that ethanol was worse than other betamimetic drugs at postponing birth until after 34 weeks’ gestation and led to a higher
rate of low birthweight babies, babies with breathing problems at birth and neonatal death (although there was no clear difference in
neonatal deaths when we restricted our analyses to the better quality studies), However, we did find that, compared to betamimetics,
ethanol was associated with a trend for fewer maternal side effects that required stopping or changing the drug, though this result is
based on three small trials. There were no differences in other secondary outcomes of preterm birth < 37 weeks, number of days delivery
was delayed, or overall maternal adverse events.
Overall, we found no evidence that ethanol was better than a placebo at postponing preterm labor and birth. Whilst there was some
evidence to suggest that ethanol may be better tolerated than betamimetics, we found that ethanol was not as effective as betamimetics
at postponing preterm labor and birth. None of the studies were long-term ones and thus none of them reported on the risk of giving
ethanol on the babies developing fetal alcohol syndrome, which can cause mental retardation.
There is no need for new studies to evaluate the use of ethanol for preventing preterm birth. However, it would be useful for long-term
follow-up studies on the babies born to mothers from the existing studies in order to assess the risk of long-term neurodevelopmental
status.
B A C K G R O U N D
Description of the condition
Preterm birth is currently recognized as the leading cause of death
in newborns worldwide (Howson 2012). According to the World
Health Organization, preterm birth is defined as delivery prior
to completion of 37 weeks’ gestation (WHO 1977). Of the es-
timated 3.1 million neonatal deaths in 2010, 35% were directly
caused by preterm birth complications (Howson 2012). The pre-
mature infants who survive are at risk for several perinatal morbidi-
ties, including respiratory distress syndrome, bronchopulmonary
dysplasia, intraventricular hemorrhage, sepsis, cerebral palsy, and
other neurologic deficits (Gladstone 2011). Neonatal morbidity
andmortality rates are inversely proportional to gestational age and
birthweight. Thus, as gestational age increases, mortality rate de-
creases (Lawn 2010). Consequently, research efforts have focused
on ways to prolong pregnancy when a woman presents in preterm
labor. Research has shown that tocolytic drugs could improve peri-
natal outcomes by inhibiting uterine contractions during preterm
labor (Conde-Agudelo 2011). Though the ultimate goal would
be to decrease the incidence of preterm birth, clinicians also use
tocolysis as a short-term treatment to delay birth long enough to
administer corticosteroids to the mother for fetal lung maturation
and to allow time to transfer the woman to a tertiary care facility
(Roberts 2006). A wide variety of tocolytic agents have been uti-
lized, including betamimetics, calcium channel blockers, oxytocin
receptor antagonists, magnesium sulfate, and ethanol. Although
ethanol is no longer used in clinical practice, this review aims to
evaluate ethanol as a tocolytic in preterm labor.
Description of the intervention
Ethanol was previously used as a common tocolytic agent. Re-
search has shown that it is an effective tocolytic when given in high
concentrations (Schaefer 2007). However, ethanol has harmful ef-
fects on the development of the fetus at these high concentrations
in maternal blood (ACOG 2011). Other research has shown that
ethanol is an ineffective tocolytic in low concentrations. Both con-
sumption and treatment with ethanol puts the fetus at risk for fetal
alcohol syndrome, which is characterized by growth retardation,
facial dysmorphia, central nervous system abnormalities, intellec-
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tual deficits, and various other birth defects. In addition, mater-
nal adverse effects, including intoxication and withdrawal, were
common. According to the American Congress of Obstetricians
and Gynecologists (ACOG), no amount of ethanol consumption
during pregnancy has been determined to be safe, and, therefore,
women should avoid ethanol entirely during pregnancy (ACOG
2011). It is due to these recommendations that the practice of
using ethanol as a tocolytic agent has been eliminated.
How the intervention might work
The mechanism for the onset of parturition is complex. There are
several known hormones and pathways that play a role in the ini-
tiation of labor. One of the most well-understood pathways is the
interaction between oxytocin and the uterus. The myometrium
has four distinct physiologic phases during pregnancy. In the
first phase, uterotropin hormones, such as estrogen, upregulate
the production of contraction-associated proteins (CAPs). These
CAPs include themyometrial receptor for oxytocin, a hormone re-
leased from the posterior pituitary and considered themost potent
agent in the stimulation of uterine contractions (Zeeman 1997).
Through this mechanism, the receptors exponentially increase in
number during pregnancy, peaking during early labor. The oxy-
tocin/oxytocin-receptor complex interacts with a G protein and
results in an influx of calcium, stimulating uterine contractions.
At high concentrations, ethanol has a tocolytic effect by acting as
an inhibitor of oxytocin release (Schaefer 2007), thus reducing the
strength of uterine contractions and decreasing the likelihood of
preterm labor.
Why it is important to do this review
Early clinical findings supported ethanol as an effective tocolytic
agent and it was a standard therapy for many years (Belinkoff
1950; Fuchs 1965; Fuchs 1967). However, ethanol is a teratogen
and can affect the fetus at any gestational age (ACOG 2011).
Therefore, it is important to assess the evidence surrounding the
benefits and harms of the use of ethanol as a tocolytic for women in
preterm labor systematically. Even though adverse-effect profiles
and potential adverse effects on the fetus have led to this therapy
not being used clinically anymore, systematically reviewing the
evidence to complete the Cochrane reviews of tocolytic therapies
is important.
OtherCochrane reviews of tocolysis include reviews ofmagnesium
sulfate (Crowther 2014), oxytocin receptor antagonists (Flenady
2014a), calcium channel blockers (Flenady 2014b), nitric oxide
donors (Duckitt 2014), betamimetics (Neilson 2014), progesta-
tional agents (Su 2014), hydration (Stan 2013), relaxin (Bain
2013), cyclo-oxygenase inhibitors (Reinebrant 2015), and combi-
nations of drugs (Vogel 2014).
O B J E C T I V E S
To determine the efficacy of ethanol in stopping preterm labor,
preventing preterm birth, and the impact of ethanol on neonatal
outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized and quasi-randomized studies. Cluster-
randomized trials and cross-over trials were not eligible for inclu-
sion. We only included studies published in abstract form if there
is enough information on methods and relevant outcomes.
Types of participants
Pregnant women admitted to hospital for threatened preterm
birth.
Types of interventions
We included any use of ethanol therapy for preterm labor.
This review included comparisons of:
1. ethanol versus placebo/usual care/no tocolytic;
2. ethanol versus a different tocolytic agent.
We planned to exclude trials that used ethanol in combination
with another tocolytic agent, unless the use of ethanol was the
only difference between the two groups (i.e. betamimetic versus
betamimetic plus ethanol).
Types of outcome measures
Primary outcomes
TheCochrane Pregnancy and Childbirth Group’s (PCG) Consen-
sus statement, “Adopting a consistent approach to PCG systematic
reviews on tocolysis for inhibiting preterm labour” was followed in
development of these outcomes. We include the core outcomes in
the consensus statement below. These core outcomes are denoted
by an asterisk.
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Maternal
1. Birth less than 48 hours after trial entry*.
2. Serious maternal adverse events (defined as death, cardiac
arrest, respiratory arrest, admission to intensive care unit)*. None
of the included trials reported on this outcome and thus no
comparisons for it were performed.
Fetal/neonatal/infant





1. Preterm birth less than 37 weeks.
2. Preterm birth less than 34 weeks*.
3. Number of days that delivery was delayed from start of
therapy.
4. Maternal adverse events (overall)*.
5. Maternal adverse events (requiring stopping or changing
drug).
Fetal/neonatal/infant
1. Serious infant outcome (defined as death or chronic lung
disease (need for supplemental oxygen at 28 days of life or later),
grade three or four intraventricular hemorrhage or
periventricular leukomalacia, major neurosensory disability
(defined as any of legal blindness, sensorineural deafness
requiring hearing aids, moderate or severe cerebral palsy, or
developmental delay/intellectual impairment (defined as
developmental quotient (DQ) or intelligence quotient (IQ) less
than two standard deviations below mean)))*.
2. Fetal alcohol syndrome/fetal alcohol spectrum disorder
(defined by the trialist or involving brain damage, impaired
growth, and head and face abnormalities).
3. Respiratory distress syndrome.
4. Birthweight.
5. Small-for-gestational age (birthweight below 10th
percentile for gestational age or as defined by trial authors).
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (31 May
2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of identified trials.
We did not apply any language or date restrictions.
Data collection and analysis
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreements through discussion. We created a study
flow diagram to map out the number of records identified, in-
cluded, and excluded.
Data extraction and management
We designed a form to extract data. For eligible studies, at least
two review authors extracted extract the data using the agreed
form.We resolved discrepancies through discussion or, if required,
we consulted a third review author. We entered data into Review
Manager (RevMan 2014), and checked them for accuracy. When
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information regarding any of the above was unclear, we attempted
to contact authors of the original reports to provide further details.
We were only successful at contacting one author to clarify an
inclusion criteria for his trial (Caritis 1982).
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreements by discussion or by involving a third review
author.
(1) Random sequence generation (checking for possible
selection bias)
For each included study, we described themethod used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study, we described the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study, we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to affect results.We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low risk of bias;
• high risk of bias;
• unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data)
For each included study and for each outcome or class of out-
comes, we described the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomized participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to out-
comes. Where sufficient information was reported, or could be
supplied by the trial authors, we re-included missing data in the
analyses that we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ’as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomization);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study, we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review were reported);
• high risk of bias (where not all the study’s prespecified
outcomes were reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so could not be used; study did not
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
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(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study, described any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there was risk of other bias.
(7) Overall risk of bias
We made explicit judgments about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we assessed the likely magnitude and
direction of the bias and whether we considered it is likely to im-
pact on the findings. We planned to explore the impact of the level
of bias through undertaking sensitivity analyses (see Sensitivity
analysis).
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented the results as summary risk
ratio with 95% confidence interval (CI).
Continuous data
For continuous data, we used the mean difference with 95% CI
where outcomes are measured in the same way between trials. We
planned to use the standardized mean difference with 95% CI to
combine trials thatmeasured the same outcome, but used different
methods.
Unit of analysis issues
Cluster-randomized trial
Cluster-randomized trials were not eligible for inclusion in this
review.
Cross-over trials
Cross-over trials were not eligible for inclusion in this review.
Other unit of analysis issues
As women with multiple gestations are at high risk of preterm
labor, it is reasonable to expect that trials will include women with
multiple gestations. Had trial authors reported data for multiple
gestations separately, we planned to perform a subgroup analysis
of women with singleton gestations versus women with multiple
gestations. We planned that if a trial excluded multiple gestations,
we would include them in the singleton gestation subgroup analy-
sis. For maternal outcomes, we would have counted the number of
pregnant women in the trial for outcomes and utilized the number
in the denominator. For neonatal/fetal outcomes, the number of
individual fetuses/newborns would have been used as the popu-
lation for outcomes and in the denominator. All of these would
have been based on the level of detail reported in the individual
trial.
If trials had includedmore than two treatment groups, we planned
to select one pair of interventions for the analysis and exclude the
others to avoid double counting as noted in theCochrane Handbook
for Systematic Reviews of Interventions Section 16.5 (Higgins 2011).
We planned to follow the Pregnancy and Childbirth Group’s con-
sensus statement for tocolytic trials. However, as this review is
mainly of historical context, we planned to separate the analyses
into two comparisons: ethanol versus placebo/control and ethanol
versus other tocolytic. As the consensus statement recommends
comparisons only between classes of drugs, this is still consistent
with this guidance as all of the comparisons that had relevant out-
comes compared ethanol to betamimetic drugs. If in future up-
dates, in the highly unlikely event of new trials being found for
inclusion that compare ethanol versus a different class of tocolytic,
we will separate out the comparisons by class. Because of this, we
plan to use a subgroup analysis based on membrane status at ad-
mission within these two comparisons.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensi-
tivity analyses.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis (i.e. we attempted to include all women
randomized to each group in the analyses, and all women were
analyzed in the group to which they were allocated, regardless of
whether or not they received the allocated intervention). The de-
nominator for each outcome in each trial is the number random-
ized minus any women whose outcomes are known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I², and Chi²statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either a Tau² was greater
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than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
Had there been10ormore studies in themeta-analysis, we planned
to investigate reporting biases (such as publication bias) using fun-
nel plots. We would have assessed funnel plot asymmetry visually.
If asymmetry was suggested by a visual assessment, we planned to
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager
(RevMan 2014). We used fixed-effect meta-analyses for combin-
ing data where it was reasonable to assume that studies were es-
timating the same underlying treatment effect (i.e. where trials
were examining the same intervention, and we judged the trials’
populations and methods sufficiently similar). If there was clin-
ical heterogeneity sufficient to expect that the underlying treat-
ment effects differed between trials, or if substantial statistical het-
erogeneity was detected, we used random-effects meta-analyses to
produce an overall summary, if a mean treatment effect across tri-
als was considered clinically meaningful. We treated the random-
effects summary as the mean of the range of possible treatment
effects and we discussed the clinical implications of treatment ef-
fects differing between trials. If the mean treatment effect was not
clinically meaningful, we would not have combined trials.
Where we used random-effects analyses, we present the results as
the mean treatment effect with 95% CI, and the estimates of Tau²
and I² statistic.
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses and sensitivity analyses.We considered whether
an overall summary was meaningful, and if it was, used random-
effects analysis to produce it.
We planned to carry out the following subgroup analyses.
1. Women with multiple gestations versus women with
singleton gestations (this subgroup analysis was not carried out
due to insufficient data).
2. Women with intact membranes versus women with
ruptured membranes. This subgroup analysis was included
following current thoughts that preterm labor that accompanies
premature preterm ruptured membranes may have a different
pathophysiology than simple preterm labor. In addition, many
older trials utilized nonspecific definitions of preterm labor for
trial entry, such that the presence of regular contractions with
minimal or no cervical dilation could qualify a woman for the
diagnosis and trial entry. These women would be less likely to
delivery preterm in general than women with ruptured
membranes. Thus, this subgroup analysis was performed as the
outcomes may be very different between them.
Subgroup analyses were restricted to primary outcomes only.
We assessed subgroup differences by interaction tests available
within Review Manager (RevMan 2014). We reported the results
of subgroup analyses quoting the Chi² statistic and P value, and
the interaction test I² statistic.
Sensitivity analysis
We expected many of the trials to be older trials and thus may not
robustly report facts related to the methodological quality of the
trial. Consequently, we planned to perform a sensitivity analysis
of trials found to be at overall low risk of bias versus all trials
to explore if there is a risk of bias associated with the quality of
some of the included trials. We planned to base this assessment
of quality mainly on the risk of bias related to randomization,
allocation concealment, and blinding parameters. However, since
there were no trials assessed as a low risk of bias, this planned
sensitivity analysis was not performed.
We also carried out sensitivity analysis where we included any
quasi-randomized trials, to explore the impact of their inclusion
on the overall results.
Planned sensitivity analyses for the primary outcomes will be con-
ducted in subsequent updates of this review (if necessary).
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
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Figure 1. Study flow diagram.
9Ethanol for preventing preterm birth in threatened preterm labor (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The search of the Cochrane Pregnancy and Childbirth Group’s
Trials Register identified 14 reports of 13 studies.
Included studies
Twelve trials involving 1586 women met the inclusion criteria
for the review. One trial contributed no data to analyses (Steer
1977). Full details on the methods and populations of each trial
are available in the Characteristics of included studies.
Two trials compared ethanol with a control/placebo of glucose or
dextrose in water (Watring 1976; Zlatnik 1972). The Steer 1977
trial compared ethanol with magnesium sulfate, and also had a
small third arm of placebo using 5% dextrose (n = 9). To avoid
double counting the ethanol group in two different comparisons,
and given the small size of the groups and clear difference in the
interventions, we opted to overcome the unit of analysis error is-
sue by selecting one of the pair-wise comparisons (ethanol versus
magnesium sulfate) and not including the dextrose group com-
parison. However, as this trial’s reported “success” outcome was
defined as stopping contractions and at least a day going by before
they started again, and did not report any of our predefined out-
comes, it did not contribute to any analyses. The remaining nine
studies compared ethanol with a betamimetic - salbutamol (Boyd
1978; Reynolds 1978; Sims 1978; Spearing 1979), terbutaline
(Caritis 1982), nylidrin (Castren 1975), fenoterol (Forster 1987
(Part II); Forster 1987 (Part III)), or ritodrine (Lauersen 1977).
The Spearing 1979 trial had a third group that received ethanol
plus indomethacin. This group was excluded from the analyses.
The trials did not use a single standard definition of preterm labor
or successful therapy.
One trial (Forster 1987 (Part II)) reported mean delay of deliv-
ery but did not report standard deviations. As it was one of the
larger trials (210 women), we believed it important to include for
this outcome. After consultation with the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), and a statisti-
cian, we imputed a range of standard deviations from 1.0 up to
the largest reported standard deviation of a trial reporting that
outcome (Sims 1978) of 24.4. No values within this range signifi-
cantly altered the results seen. Thus, values similar to the majority
of standard deviations in that comparison (~3.3) were utilized in
the final analysis. This limits conclusions from this comparison
somewhat (Analysis 2.6).
Four trials excluded women with ruptured membranes (Forster
1987 (Part II); Steer 1977; Watring 1976; Zlatnik 1972). Of the
other trials, two specified outcomes for those with intact versus
ruptured membranes (Caritis 1982; Sims 1978), allowing for the
subgroup analyses.
Three trials excluded multiple gestations (Sims 1978; Steer 1977;
Watring 1976), and two reported outcomes separately for sin-
gleton and multiple gestations (Lauersen 1977; Spearing 1979).
However, since there were so few women in the trials withmultiple
gestations and the outcome reported was birth < 72 hours, which
was not a prespecified outcome, we did not perform that planned
subgroup analysis.
Six trials (Castren 1975; Forster 1987 (Part II); Forster 1987 (Part
III); Reynolds 1978; Spearing 1979; Steer 1977) had randomiza-
tion methods that qualified as quasi-randomized. In the sensitivity
analysis, these trials were excluded.
Excluded studies
One trial was excluded as it did not report trial data regarding
ethanol as a tocolytic (Waltman 1969). For more information
please see Characteristics of excluded studies.
Risk of bias in included studies
In general, the quality of trial reporting was low. This is likely due
to the years of publication of many of the studies being well prior
to the CONSORT (Consolidated Standards of Reporting Trials)
criteria (Schulz 2010), or any attempts at standard reporting of
trials. Thus, the assessment of risk of bias in several areas is unclear
simply because they are not stated (see Figure 2; Figure 3).
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
12Ethanol for preventing preterm birth in threatened preterm labor (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Random sequence generation
Only three trials had a low risk of bias for random sequence gener-
ation. (Caritis 1982; Lauersen 1977; Watring 1976). The Zlatnik
1972 trial stated that assignments were “random” in envelopes
without any details about how randomization occurred. Six of the
trials (Castren 1975; Forster 1987 (Part II); Forster 1987 (Part III);
Reynolds 1978; Spearing 1979; Steer 1977) contained high risk
of bias for random sequence generation. This is due to generally
stating that randomization/allocation was based on alternating al-
location or based on last names.
Allocation concealment
While all three of the above trials (Caritis 1982; Lauersen 1977;
Watring 1976) used envelopes for allocation, none stated if the
envelopes were sequentially numbered or opaque and thus all were
unclear in the risk of allocation bias. A fourth had low risk of bias
for allocation concealment however, only stated that assignments
were “random” in the envelopes (Zlatnik 1972). Six of the trials
(Castren 1975; Forster 1987 (Part II); Forster 1987 (Part III);
Reynolds 1978; Spearing 1979; Steer 1977) contained high risk of
bias for allocation concealment.Often thiswas due to “alternating”
allocationor randomizationbased on surnames or recordnumbers.
Blinding
Only theWatring 1976 trial stated that it was “single blind” in the
title. However, it was not stated in the trial report which group was
blinded. The control group in this study were given morphine or
secobarbital so may have appeared similarly “intoxicated” as the
ethanol group. Seven trials stated that they were unable to blind
providers or women (Caritis 1982; Castren 1975; Forster 1987
(Part II); Forster 1987 (Part III); Lauersen 1977; Reynolds 1978;
Sims 1978). In the remaining trials, blinding was not stated for
these groups, however it is likely that blinding in a study of ethanol
such as this would be difficult. No trial separately reported if the
outcomes assessors were blinded, thus all were rated as unclear.
Attrition, reporting, and other sources of bias
Generally, the trials had low risk of bias for attrition and reporting
and did not have other sources of bias. The Forster 1987 (Part II)
trial initially had a placebo group but after noting “no change” in
the first 10 participants, these women were then split into groups
one and two for the remainder of the study. This may have led to
other bias. The Zlatnik 1972 trial also was rated as a potentially
high risk of other bias due to only stopping the trial “when the plot
of data indicated one treatment superior to the other” and that
while they stated the demographic characteristics were the same
for the two groups, they did not show these data.
Thus, none of the trials would easily be categorized as low risk
of bias. The Caritis 1982; Lauersen 1977; Watring 1976; Zlatnik
1972 trials appear to be at a lower risk of bias than the rest of the
trials of lower quality. As these trials reported different outcomes
in different comparisons and they are not clearly low risk of bias,
no subgroup analyses based on trial quality was performed.
Effects of interventions
Ethanol versus placebo/control - comparison 1 (two
trials, 77 women)
Primary outcomes
The two trials included in this comparison (Watring 1976; Zlatnik
1972), did not report on any of the same outcomes. Both trials
excluded women with ruptured membranes so the only subgroup
of relevance is that of women with intact membranes for these
analyses. There were no significant differences in any of the pri-
mary outcomes with data: birth < 48 hours after trial entry (one
trial, 35 women; risk ratio (RR) 0.93, 95% confidence interval
(CI) 0.43 to 2.00 (Analysis 1.1)); neonatal mortality (one trial,
35 women; RR 1.06, 95% CI 0.31 to 3.58 (Analysis 1.3)). Both
of these results were from the Watring 1976 trial. Perinatal mor-
tality was not reported in either trial. Serious maternal adverse
events were also not reported.
Secondary outcomes
There were no differences in this comparison for any of the sec-
ondary outcomes that were reported, although all comparisons
were based on only one of the trials: preterm birth < 37 weeks (RR
1.29, 95% CI 0.72 to 2.31 (Analysis 1.4)); preterm birth < 34
weeks (RR 1.69, 95% CI 0.69 to 4.16 (Analysis 1.5)); number of
days delivery was delayed (mean difference (MD) -3.43 days, 95%
CI -22.74 to 15.88 (Analysis 1.6)); respiratory distress syndrome
(RR 0.85, 95% CI 0.27 to 2.64 (Analysis 1.9)), or birthweight <
2500 g (RR 1.41, 95% CI 0.81 to 2.46 (Analysis 1.10)), all from
the Watring 1976 trial (one trial, 35 women).
The risk ofmaternal adverse events requiring stopping or changing
the drug was not estimable due to there being no events in either
arm for the one trial (42 women) (Analysis 1.8) that reported this (
Zlatnik 1972). Additionally, theZlatnik 1972 trial did report delay
until delivery but reported it as a median with no mention of the
standard deviation (median 19 days in ethanol group versus “less
than 1” day in the glucose/water group). No data were presented
for the other prespecified secondary outcomes: maternal adverse
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events overall; serious infant outcome; fetal alcohol syndrome/fetal
alcohol spectrum disorder; small-for-gestational age.
Ethanol versus other tocolytic (betamimetics) -
comparison 2 (nine trials, 1438 women)
The Steer 1977 trial defined success as contractions stopping and
not restarting for 24 hours. As it did not have any reported out-
comes prespecified in this review, it did not contribute to the
analyses. Thus, all comparisons below compare ethanol to a be-
tamimetic drug.
Primary outcomes
Compared to other tocolytic drugs (all involved a comparison of
ethanol to betamimetics), ethanol treatment was associated with
no clear difference in births < 48 hours after trial entry (three
trials, 192 women; average RR 1.12, 95% CI 0.53 to 2.37, Tau² =
0.19; I² = 59%Analysis 2.1,) orperinatal mortality (six trials, 698
women; RR 1.20, 95% CI 0.78 to 1.84, Analysis 2.2), but higher
rates of neonatal mortality (eight trials, 1238 women; RR 1.43,
95% CI 1.02 to 2.02, Analysis 2.3)). Serious maternal adverse
events were not reported
Subgroup analysis
For the subgroup analysis comparing women with intact mem-
branes versus those with ruptured membranes, only one trial
presented some data stratified by ruptured or intact membranes
(Caritis 1982). Two other trials excluded women with ruptured
membranes (Castren 1975; Lauersen 1977) and thus are included
in the subgroup of studies limited to women with intact mem-
branes. The other trials either did not specify membrane status
in their inclusion/exclusion criteria or in their reporting. These
are included in the “women without specified membrane status”
subgroup. We carried out subgroup analysis by membrane status,
comparing women with intact membranes, those with ruptured
membranes and thosewithout specifiedmembrane status.Wewere
able to carry out these subgroup analyses for perinatal mortality
and neonatal mortality but these analyses did not change the re-
sults - there were no significant subgroup interactions: perinatal
mortality (test for subgroup differences: Chi² = 1.00, df = 2 (P =
0.61), I² = 0%); neonatal mortality (test for subgroup differences:
Chi² = 1.21, df = 2 (P = 0.55), I² = 0%).
Sensitivity analysis
Excluding quasi-randomized trials did not significantly change
the results of the primary outcome analyses with the exception of
making the results for neonatal mortality no longer statistically
significant (3 trials, 330 women; RR 1.49, 95% CI 0.82 to 2.72).
Secondary outcomes
Therewas no clear difference in the rate of pretermbirth <37weeks
between the groupofwomenwhowere given ethanol, compared to
those women who received betamimetics (four trials, 741 women;
average RR 1.08, 95% CI 0.86 to 1.36, random-effects analysis,
Tau² = 0.03; I² = 66% (Analysis 2.4)). In contrast, ethanol was
associated with higher rates of preterm birth < 34 weeks (two
trials, 599 women; RR 1.56, 95% CI 1.11 to 2.19 (Analysis 2.5)).
There was no clear difference between the ethanol group and the
betamimetic control in terms of the number of days delivery was
delayed (five trials, 585 women; MD -2.51, 95% CI -11.11 to
6.09, random-effects analysis, Tau² =91.57;Heterogeneity: Tau² =
91.57; I² = 99% (Analysis 2.6)), or overall maternal adverse events
(four trials, 350 women, average RR 0.99, 95% CI 0.46 to 2.11,
random-effects analysis, Tau² = 0.50; I² = 88% (Analysis 2.7)).
Compared to betamimetics, however, ethanol was associated with
a trend towards a lower rate of maternal adverse events requiring
stopping or changing the drug (three trials, 214 women; RR 0.25,
95% CI 0.06 to 0.97, Analysis 2.8).
Ethanol usewas associatedwith higher rates of neonatal respiratory
distress syndrome (three trials, 823 women; RR 1.76, 95% CI
1.33 to 2.33 (Analysis 2.9)), and higher rates for babies with a
birthweight of less than < 2500 g (five trials, 834 women; RR 1.30,
95% CI 1.09 to 1.54 (Analysis 2.10)).
These outcomes are likely all related to the lower incidence of
preterm birth seen with other tocolytics, which for all these com-
parisons were betamimetics. The results for neonatal mortality
must be viewed with additional caution as some trials did not re-
port both perinatal mortality and neonatal mortality. Due to high
measures of heterogeneity, random-effects models were used for
the outcomes of preterm birth < 37 weeks, number of days de-
livery delayed, and overall maternal adverse events (Analysis 2.4;
Analysis 2.6; Analysis 2.7).
D I S C U S S I O N
Summary of main results
While early clinical findings supported the use of ethanol as a to-
colytic (Fuchs 1965), concerns about its effectiveness and for fetal
safety lead to it falling out of favor (ACOG 2011). Consequently,
the trials available for this review are all fairly dated with the most
recent one being published in 1987. There was much inconsis-
tency in the data reported in these studies. In addition, all of these
trials were completed before the routine use of antenatal corticos-
teroids, which may be responsible for some of the higher rates of
neonatal mortality and respiratory distress syndrome seen in these
trials.
Twelve studies involving 1586 women were available for review. In
two of these studies with 77 women, ethanol was compared with
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placebo/control. The majority, nine studies with 1438 women,
compared ethanol with another tocolytic (in this instance, all be-
tamimetic agents). Spearing 1979 had a third group that received
ethanol plus indomethacin and they excluded this arm. Steer 1977
compared ethanol and magnesium but contributed no data to the
review.
Compared to placebo, ethanol was no different for birth < 48
hours after trial entry, perinatal mortality, neonatal mortality, or
any of the secondary outcomes of pretermbirth < 37 or < 34weeks’
gestation, adverse events, or neonatal outcomes.
Compared to betamimetic drugs, ethanol had a higher risk
of neonatal mortality (although this difference was not appar-
ent when our analysis excluded quasi-RCTs). Compared to be-
tamimetics, ethanol was not different in regards to birth < 48 hours
or perinatal mortality, preterm birth < 37 weeks, or number of
days delivery was delayed. However, ethanol was associated with
a higher rate of preterm birth < 34 weeks and respiratory distress
syndrome and low birthweight babies. Compared to betamimetics
though, ethanol was associated with a trend towards a lower rate
of maternal side effects requiring stopping the drug.
From the available data, there is no evidence of ethanol being
superior to placebo and it appears to be inferior to betamimetics in
many aspects. Subgroup analysis (for our comparison of ethanol
versus betamimetic) did not substantially change these findings,
although the number of trials for subgroup analyses was limited.
The only advantage shown for ethanol was a trend suggesting that
it may be better tolerated than betamimetic therapy, although this
is based on few trials with small samples sizes so this result should
be interpreted with caution.
Overall completeness and applicability of
evidence
There were no data available to investigate any possible association
between ethanol as a tocolytic and fetal alcohol syndrome. Alco-
hol use in pregnancy is the leading cause of preventable mental
retardation (ACOG 2011). None of the studies identified using
ethanol as a tocolytic contained long-term neurodevelopmental
follow-up of the offspring. This does open a potential avenue for
future research. Long-term follow-up of the participants in these
studies could provide information about any possible cognitive
effect that ethanol may have had on the exposed fetuses during
labor.
The evidence obtained is relatively old and is complete as ethanol
use is essentially obsolete currently due to fetal alcohol syndrome
concerns. Thus, it is unlikely any new randomized controlled trials
on the topic area will be forthcoming. As such, the evidence’s
applicability is limited because the therapy is no longer in clinical
use.
Quality of the evidence
The quality of the evidence mostly has a high risk of bias, with
very few studies that are of at least moderate quality. No truly low
’Risk of bias’ studies were identified. Much of the assessments were
based on uncertainty because trials in that era did not clearly state
all methods for the study as they were before CONSORT.
Potential biases in the review process
As this is a historical therapy no longer used, it is possible that
reports were graded more harshly. The two Forster studies Forster
1987 (Part II); Forster 1987 (Part III) were in German and it
is possible that the translations missed some information. These
reasons are both felt to be unlikely.
Agreements and disagreements with other
studies or reviews
We found no difference in outcomes of ethanol compared to
placebo, but when compared mainly to betamimetics, that be-
tamimetics were superior in delaying delivery and reducing
preterm birth. This corroborates the Cochrane review of be-
tamimetics that found they were superior to placebo/control at
delaying delivery (Neilson 2014). This review found that, com-
pared to betamimetics though, ethanol was associated with a trend
towards a lower rate of maternal side effects requiring stopping the
drug. This is consistent with observations in other studies which
report that, compared to placebo, betamimetics are associatedwith
higher levels of side effects resulting in the need for a change in
medication (Haas 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Historically, ethanol was used as a common tocolytic agent but
is no longer used in practice due to safety concerns for both the
mother and her baby. There is no evidence that ethanol is superior
to placebo or to betamimetic drugs.
Implications for research
While there is no current need for research regarding ethanol as
a tocolytic, long-term follow-up studies on offspring from older
trials to assess the risk of long-term neurodevelopmental status
would be useful.
A C K N OW L E D G E M E N T S
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As part of the pre-publication editorial process, this review has
been commented on by three peers (an editor and two referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Preg-
nancy and Childbirth. The views and opinions expressed therein
are those of the authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, NHS or the Department
of Health.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boyd 1978
Methods Design: this study randomized and analyzed 96 women in preterm labor. The methods
of allocation/randomization are unknown
Sample size: 96 (not calculated before trial).
Setting: the study was conducted at the Institute of Obstetrics & Gynaecology, Queen
Charlotte’s Hospital in London
Participants Patients in spontaneous preterm labor having 6 or more uterine contractions per hour
between the 27th and 35th week of pregnancy were included in the study. Patients with
cervical dilation of more than 4 cm or uterine bleeding were excluded. A total of 96
women were entered into the trial
Interventions IV salbutamol: an initial dose of 5 ug/minute being increased to 50 ug/minute until
contractions ceased or side effects precluded further increments
IV ethanol: an initial dose of 30 mL/hour for 2 hours followed by 3 mL/hour
Each regimen was continued for 12 hours and repeated up to 5 times if labor had not
ceased. No oral therapy was used
Outcomes Delivery prevented before the 37th week of gestation.
Delivery within 24 hours of admission to the study.
Notes Only have the abstract.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “allocated randomly”, but it is un-
clear how.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk Not stated.
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Boyd 1978 (Continued)
Other bias Unclear risk Not stated.
Caritis 1982
Methods Design: this was a randomized controlled trial.
Sample size: 92 (not prespecified).
Setting: Magee-Women’s Hostpital in Pittsburgh.
Participants Women were included in the study if the following conditions were met
(1) Regular painful uterine contractions were documented by a tocodynamometer and
occurred at least every 5 to 7 minutes, lasted at least 30 seconds, and occurred for a
minimum of 1 hour
(2) The gestational age was between 20 and 36 weeks in women with intact membranes
and between 24 and 34 weeks in women with ruptured membranes
(3) There were no obstetric or medical contraindications to the inhibition of labor or to
the use of the labor-inhibiting drug
Women were excluded if they had received another labor-inhibiting drug for the current
episode of preterm labor or if cervical dilation was greater than 5 cm
Patients with rupture of membranes were analyzed as a subgroup
This study randomized 92 women, but only analyzed 88 women (4 women were with-
drawn because they did not fulfil the inclusion criteria)
Interventions IV ethanol: a loading dose of 7.5mL/kg/hour of 10% ethanol in 5%dextrose was infused
for 2 hours. This was followed by a maintenance infusion of ethanol at a rate of 1.5 mL/
kg/hour for 10 hours. If labor recurred, a second or third course of ethanol was given.
For repeated courses, the reloading dose was reduced by 10% for each hour less than 10
elapsing from the end of the previous maintenance infusion
IV terbutaline: terbutaline was dilutedwith physiologic saline solution to a concentration
of 20 ug/mL. Physiologic saline solution (400 mL) was infused over 20 minutes before
the administration of terbutaline. The rate of infusion of terbutaline was started at 5
ug/minute and was increased by 5 ug/minute every 20 minutes to a maximal dosage
of 30 ug/minute or until uterine contractions were abolished or maternal side effects
occurred. Once contractions were abolished, the infusion was maintained at that rate
for 1 hour, then, the rate of infusion was reduced to the minimal dose (5-10 ug/minute)
required to inhibit labor and was maintained at that rate for an additional 8 hours. If
labor recurred during the 8-hour maintenance infusion, the rate was increased until labor
again subsided, and the entire maintenance infusion was again initiated
All women with intact membranes in whom labor was inhibited received 5 mg of terbu-
taline orally 30 minutes before the end of the IV maintenance infusion. This dosage was
repeated 4 times daily for 5 days. No oral medication was given to women with rupture
of membranes
Outcomes Completely successful: pregnancy maintained beyond 36 weeks.
Partially successful: prevented delivery or progression of cervical dilation during IV ther-
apy, at least until a mature L/S ratio was obtained or until a full course of betamethasone
could be given to the mother to enhance fetal lung maturation
Failed: side effects or drug intolerance led to discontinuation of an assigned drug treat-
ment, and the patient continued to experience labor
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Caritis 1982 (Continued)
Notes Bethamethasone (12 mg) was given IM 2 times, 24 hours apart to all women. A course
was considered to be complete 36 hours after the first injection
If treatment failed, a second labor-inhibiting drug, magnesium sulfate, was started
Women with rupture of membranes: Objective was to maintain pregnancy for 36 hours.
Thus, no further labor-inhibiting therapy was given after 36 hours, but induction of
labor was not encouraged until labor recurred or signs of chorioamnionitis or fetal distress
were detected
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random number generator.
Allocation concealment (selection bias) Unclear risk Neither physician nor patient was aware
of the treatment modality until informed
consent had been signed. Then a sealed
envelope containing 1 of 2 randomly as-
signed treatment protocols was opened and
the treatment was identified. Thus, no one
aware until after randomization. However,
unclear if the envelope was opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Knew after enveloped was opened.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Low risk 4 of the 92 women were excluded in the
review because they did not meet the inclu-
sion criteria
Other bias Low risk None.
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Castren 1975
Methods Design: the study was a “quasi” randomized controlled trial.
Sample Size:194 (not prespecified).
Setting: the trials were performed at theUniversity CentralHospital of Helsinki (nylidrin
versus ethanol) and the Midwifery Institute Hospital (isoxuprine versus placebo)
Participants Partcipants in this study were pregnant women between 24 and 36 weeks’ gestation in
premature labor. Inclusion criteria were intactmembranes and active uterine contractions
Interventions Treatment with the randomized protocol was started on admission. Treatment was as
follows
University Central Hospital of Helsinki: Nylidrin (50 mg IV over 6 hours, then approx-
imately 65 mg IM over 57 hours, then 6 mg PO every 5 hours) versus ethanol (128 mL
IV over 6 hours, then 40 mL of cognac every 6 hours, which was prescribed to continue
at home upon discharge)
Midwifery Institute Hospital: isoxuprine (25mg IV over 1 hour, then 160mg IM over 60
hours, then 10 mg PO every 4 hours continued after discharge) versus placebo (followed
the protocol as described for nylidrin)
Outcomes The reported outcome as “successful” treatment defined as the premature contractions
were arrested and pregnancy prolonged such that the birthweight was >/= 2500 g, or
that the pregnancy was prolonged by 7 days and the pregnancy continued until at least
the 37th week of gestational age. Thus this trial contained the outcome of preterm birth
< 37 weeks only
Notes We analyzed the women from the University Central Hospital of Helsinki since these
women were the group randomized to nylidrin or ethyl alcohol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Alternating based on admission.
Allocation concealment (selection bias) High risk Alternating allocation based on admission.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Based on protocol, it was not possible to
blind participants or providers, especially
with women who became intoxicated with
ethanol
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
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Castren 1975 (Continued)
Selective reporting (reporting bias) Unclear risk Method of reporting makes it unclear if all
outcomes are reported for the comparisons.
No prespecified outcomes stated in Meth-
ods
Other bias Unclear risk Itwas reported that the study obtained their
pharmaceuticals directly from the pharma-
ceutical companies. It was unclear whether
these were paid for or not
Forster 1987 (Part II)
Methods Design: this was a parallel randomized study.
Sample size: 223 (not prespecified).
Setting: Germany.
Participants Women were included in this study if they were pregnant and experiencing premature
labor. The exclusion criteria were not specified
Interventions This was a parallel study with 3 groups.
Group 1: fenoterol (1-3 ug/minute).
Group 2: ethanol 50 in a fructose solution (20 gtt/minute).
Group 3: placebo (glucose 50), however the first 10 women showed no change with
placebo and were therefore divided into Groups 1 and 2 for the rest of the study
Outcomes Measured outcomes included birthweight, length of gestation extended, mortality rate,
morbidity rate in relation to RDS
Notes Review was originally written in German. Information here is found on the Cochrane
Pregnancy and Childbirth Group Translation Form and original report tables
1 patient’s pregnancy ended in abortion, but it appears that they were included in the
data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients were split into groups by last name,
not randomized
Allocation concealment (selection bias) High risk Last name would be known on admission.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind participants and person-
nel during treatment if women were intox-
icated with ethanol
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Forster 1987 (Part II) (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears to be no attrition bias noted in the
translation document
Selective reporting (reporting bias) Unclear risk Not stated in translation form.
Other bias High risk There were originally 3 groups but the
study designers divided the placebo group
into the 2 study groups when there was no
change from placebo in the study
Forster 1987 (Part III)
Methods Design: this was a parallel randomized study.
Sample size: 464 (not prespecified).
Setting: Germany.
Participants Women were included in this study if they were pregnant and experiencing premature
labor. The exclusion criteria was not specified. All women were approximately 32 weeks’
gestation
Interventions There were 4 treatment groups.
Group 1: long-term ethanol.
Group 2: long-term partusisten.
Group 3: short-term ethanol.
Group 4: short-term partusisten.
Due to a limited translation form, we combined the data for the long term and short
term for both treatments
Outcomes What determined a success was based on the length of the gestation period; the weight,
Apgar score, RDS mortality, maturation level, neonatal morbidity; prolongation index
and success score
Notes Review was originally written in German. Information here is found on the Cochrane
Pregnancy and Childbirth Group Translation Form
2 women’ participation ended in abortion, but it appears that they were included in the
data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients were split into groups by last name,
not randomized
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Forster 1987 (Part III) (Continued)
Allocation concealment (selection bias) High risk Last name would be known on admission.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind participants and person-
nel during treatment if women were intox-
icated with ethanol
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in translation form.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears to be no attrition bias noted in the
translation document
Selective reporting (reporting bias) Unclear risk Not stated in translation form.
Other bias Unclear risk Not stated in translation form.
Lauersen 1977
Methods Design: randomized controlled trial.
Sample size: 135 women with threatened premature labor from 3 collaborating centers
(not prespecified)
Setting: 3 collaborating centers- New York, NY; Cleveland, OH, and East Meadows,
NY- all in United States
Participants Patient included in this study fulfilled the following criteria:
(1) regular uterine contractions of 30-60 seconds’ duration at least once every 10minutes
and clinically judged as premature labor;
(2) pregnancy between 20 and 36 weeks;
(3) estimated fetal weight below 2500 g;
(4) uterine fundus above the umbilicus;
(5) membranes intact and not bulging;
(6) cervical effacement; and
(7) cervical dilation not exceeding 4 cm. Exclusion criteria were as follows: (1) premature
separation of the placenta, (2) pre-eclampsia, chronic renal disease, chronic hypertension,
cardiac disease, diabetes mellitus, and other severe maternal diseases, (3) presence of a
dead or malformed fetus, (4) placenta previa if bleeding was severe enough to require
intervention, and (5) anymaternal or fetal complication that required immediate delivery
Interventions Patients were randomized to either the ritodrine group (68 women) or ethanol group
(67 women)
Ritodrine group: IV infusion of 50 ug/minute of ritodrine, which was increased by 50 ug
every 10 minutes until adequate uterine relaxation occurred, with a maximum infusion
rate of 350 ug/minute. The optimal dose for each patient was maintained for 12 hours.
30 minutes prior to termination of infusion, oral ritodrine was started and women were
discharged on ritodrine orally in doses ranging from 20 to 60 mg daily maintained for
4 weeks or until 38 weeks’ gestation, whichever came first
Ethanol group: a loading dose infusion of 7.5 mL/kg/hour ethanol was given for 2
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Lauersen 1977 (Continued)
hours, followed by maintenance dose of 1.5 mL/kg/hour for 10 hours. If premature
labor recurred after the ethanol infusion, up to 2 additional courses following the same
protocol were permitted
Outcomes Measured outcomes included (1) delivery postponed for more than 72 hours, (2) time
gained, (3) gestational age at time of delivery, (4) perinatal mortality, and (5) infant
morbidity in relation to RDS
Notes 150 randomized initially, later 15 found to not meet inclusion criteria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly drawn sealed envelopes were
used for randomization.
Allocation concealment (selection bias) Unclear risk Likely low risk as stated sealed envelopes.
However, unclear if the envelope was
opaque thus rated as Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind participants and person-
nel during treatment if women were intox-
icated with ethanol
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Low risk No reporting bias.
Other bias Low risk None identified.
Reynolds 1978
Methods Design: randomized controlled trial.
Sample size: 84 women (not prespecified).
Setting: not specified but author from Hammersmith Hospital, London
Participants In this study, 84 women in premature labor were selected for the trial. Inclusion criteria
were gestational age between 20 and 37 weeks and contractions occurring at least every
10 minutes. Exclusions from participation included major maternal complications, the
cervix dilated more than 5 cm, amnionitis, or significant hemorrhage
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Reynolds 1978 (Continued)
Interventions Group 1: salbutamol infusion until titrated to 40 ug/minute, uterine contractions ceased,
or patient became tachycardic. 200 mg sodium phenobarbitone also given to women in
this group
Group 2: ethanol 10-hour treatment according to the Fuchs 1967 protocol.
Outcomes The criterion for success was an inhibition of labor for 24 hours
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients were alternated to the 2 groups.
Allocation concealment (selection bias) High risk Alternate allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind participants and person-
nel during treatment if women were intox-
icated with ethanol
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Unclear risk No prespecified outcomes other than inhi-
bition of labor for 24 hours
Other bias Low risk None identified.
Sims 1978
Methods Design: randomized trial.
Sample size: 100women (not prespecified).Only 88 of the 100were analyzed. 12women
were withdrawn (8 sets of twins, 2 < 27 weeks, 1 placenta previa, 1 lost records)
Setting: Institute of Obstetrics & Gynaecology, Queen Charlotte’s Hospital in London
Participants All women admitted in labor between 27 and 35 weeks’ gestation were invited to join
the study whether the membranes were intact or ruptured. The diagnosis of labor was
made on a history of 6 or more contractions per hour
Patients were not considered in cases ofmultiple pregnancies, if postponement of delivery
was contraindicated, or if cervix was more than 4 cm dilated
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Sims 1978 (Continued)
Interventions IV ethanol: a solution of 10% v/v ethanol in 5% dextrose in water was prepared. The
solution was administered intravenously at the rate of 15 mL/kg of body weight over the
first 2-hour period. A maintenance infusion of 1.5 mL/kg of body weight per hour was
administered for a further 10 hours. If contractions reappeared after discontinuation,
the treatment was repeated
IV salbutamol: a solution of 4 mg salbutamol in 500 mL of 5% dextrose in water was
prepared. The solution was administered intravenously at 5 ug of salbutamol per minute.
The infusion rate was increased by 5 ug of salbutamol per minute every 10 minutes until
either (a) contractions were abolished, (b) a maximum rate of 50 ug per minute was
attained, or (c) until unacceptable side effects occurred. The infusion rate wasmaintained
at the lowest rate to stop contractions for a total of 12 hours (24 hours for ruptured
membranes). If contractions reappeared the treatment was repeated
Betamethasone therapy: each patient received either 4 mg of betamethasone IM or saline
placebo IM according to a randomized scheme. These injections were repeated 8 hourly
for 6 doses
Outcomes Delay delivery for at least 24 hours.
Delay delivery for at least 48 hours.
Delivery after 37 weeks.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States there was a “randomized list”, but
there is not enough detail
Allocation concealment (selection bias) Unclear risk Not stated.




Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Low risk No reporting bias.
Other bias Low risk None.
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Spearing 1979
Methods Design: randomized trial.
Sample size: 66 women (not prespecified). Only 62 of the 66 were analyzed. 4 women
were withdrawn due to drug administration protocol violations
Setting: University of Bristol, UK.
Participants Patients were admitted to the trial if they were in labor (regular painful contractions
occurring at least once every 10minutes) between26 and35 completedweeks of gestation
inclusive, and in whom arrest of labor was considered advisable. Those women with
multiple pregnancy, threatened premature labor with show, and suspected rupture of
membranes were included
Patients with antepartum hemorrhage, known fetal abnormality, and gross hydramnios
were considered reasons for exclusion
Interventions Treatment was selected in sequence in the labor room.
IV ethanol: ethanol was prepared as a 10% solution in 5% dextrose. A loading dose of
15 mL/kg of body weight was infused over 2 hours followed by a maintenance dose of
1.5 mL/kg of body weight
IV ethanol + indomethacin: ethanol was given as previously stated. 100 mg of in-
domethacin was given as a rectal suppository, and a similar dose was given after 12 hours.
After 24 hours, this was continued orally with 25 mg every 6 hours for 48 hours after
cessation of contractions
IV salbutamol: 5 mL of salbutamol to 500 mL of 5% dextrose was prepared, giving a
concentration of 10 ug/mL. Infusion began at 20 drops/minute increased by increments
of 10 drops/minute every 10 minutes until contractions ceased. The maximum infusion
rate was 80 drops/minute or less if the maternal pulse rate exceeded 140 bpm or other
maternal distress occurred (palpitations or hypotension). With cessation of contractions
the infusion was maintained at the successful level for 6 hours and then gradually de-
creased. Treatment was continued with oral salbutamol 4 mg four times a day and con-
tinued for at least 48 hours
2 infusions of any treatment were allowed.
Outcomes Success: uterine activity ceased and did not return until 36 weeks or later, or returned
only after 48 hours free of labor
Notes In the cases of failure, treatment was changed.
Only the data from the IV ethanol and IV salbutamol were included in our analysis
because it was unclear whether the effects of the ethanol + indomethacin were due to
the Indomethacin or the combination of the 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Treatment was selected in sequence in the
labor room, and the patient’s name was
added to a list which indicated the treat-
ment to be given.”
Allocation concealment (selection bias) High risk “Selected in sequence.”
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Spearing 1979 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Low risk No reporting bias.
Other bias Low risk None.
Steer 1977
Methods Design: randomized controlled trial.
Sample size: 71 (not prespecified).
Setting: Sloane Hospital for Women of the Columbia-Presbyterian Medical Center in
New York
Participants Patients in the study included those who met all of the following criteria: (1) there was
a painful, identifiable contraction pattern with a frequency of 5 minutes or less, (2) the
duration of the pregnancy was less than 37 weeks, (3) the estimated fetal weight was less
than 2500 g, (4) the amnion was intact, and (5) cervical dilation was less than 5 cm
Patients with a fever due to amnionitis or those with bleeding greater than “show” were
excluded from the study
Interventions IV ethanol: a solution of 9.5% v/v ethanol in 5% dextrose in water was administered
intravenously at the rate of 15mL/kg of bodyweight over the first 2 hours. Amaintenance
infusion rate of 1.5 mL/kg of body weight per hour was administered until signs of labor
had subsided or labor had progressed to an irreversible stage. If contractions reappeared
after discontinuation, the procedure was repeated
IV magnesium sulfate: a 2% maintenance solution was prepared by adding 200 mL of
10% magnesium sulfate to 800 mL of 5% dextrose in water. 4 g of magnesium sulfate
was infused intravenously, slowly enough to avoid flushing and vomiting. A constant
infusion of the 2%maintenance solutionwas then given at 100mL/hour. This continued
until labor had subsided or labor had progressed to an irreversible stage. The rate was
reduced if magnesium toxicity was observed. If contractions reappeared, the procedure
was repeated
IV dextrose in water: a solution of 5% dextrose in water was infused intravenously at
100 mL/hour
Outcomes Success: contractions stopped and aperiod of at least 24hourswent by before contractions
occurred again
Notes
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Steer 1977 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patient received treatment according to the
last digit of their hospital number (not truly
random). A small group of women were
chosen at random to receive the dextrose in
water for a control group
Allocation concealment (selection bias) High risk Last digit of medical record number.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Low risk No reporting bias.
Other bias Low risk None.
Watring 1976
Methods Design: single-blind randomized trial.
Sample size: 35 women (not prespecified).
Setting: Tripler Army Medical Center in San Francisco, CA in the United States
Participants Criteria for inclusion in this study were as follows. (1) a living, single gestation between
24 and 36 weeks. (2) a history of painful uterine contractions less than 10 minutes
apart for 1 hour or more. (3) regular uterine contractions as determined by palpation
and tokodynamometer. (4) greater than 50% effacement of the cervix with or without
dilation. (5) absence of complications such as bleeding, premature rupture ofmembranes,
and fever. (6) no history of incompetent cervical os
Interventions Study group: received an IV infusion of 5% ethanol in 5% dextrose in water. A loading
dose of 15 cc/lb/2 hour and a maintenance dose of 10% of the total loading dose per
hour until the contractions had ceased for at least 6 hours. If contractions were still
present after 4 hours or if they recurred within 24 hours, one-half of the loading dose
was given in 1 hour and the maintenance dose continued for a total of 12 hours. After
contractions ceased, women were kept on bed rest for 24 hours. Then, women were on
a 24 ambulation period. If no contractions occurred, patient was discharged
Control group: usually treated with either morphine sulfate or secobarbital and ambu-
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Watring 1976 (Continued)
lated on the same schedule
Outcomes Success: patient remained without contractions for 72 hours following treatment
Notes If contractions recurred for a third time, no attempt was made to stop labor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Groups of 10 cards, 5 treatment and 5 con-
trol, were placed in an envelope fromwhich
they were drawn by a disinterested, third
party. When all cards had been drawn, an-
other group of 10 cards was placed in the
envelope and the process repeated
Allocation concealment (selection bias) Unclear risk Drawn from envelope. However, unclear if
the envelope was opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Single blind” but unclear which groupwas
actually blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Low risk No reporting bias.
Other bias Low risk None.
Zlatnik 1972
Methods Design: randomized controlled trial.
Sample size: 42 women (not prespecified).
Setting: New York Hospital-Cornell Medical Center in the United States
Participants Patients admitted to the hospital with threatened premature labor were included in the
study if stopping labor was deemed advisable
Patients were excluded from the study if delivery seemed imminent, the membranes
were ruptured, or the patient was bleeding actively or had some other factor which
contraindicated the continuation of pregnancy
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Zlatnik 1972 (Continued)
Interventions IV ethanol: 9.5% ethanol solution.
IV glucose: 5% glucose in water.
Patients received 15 mL/kg of the assigned solution intravenously over a 2 hour period
as a loading dose and then 1.5 mL/kg per hour as a maintenance dose for an additional
6 to 10 hours. If labor actively progressed so that delivery seemed imminent, the ethanol
was discontinued. If labor stopped, but later recurred, the assigned solution was again
administered as outlined above
Outcomes Success: delivery did not occur within 72 hours.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated “therewas randomassignment of the
two treatments to the numbered envelopes”
Allocation concealment (selection bias) Low risk Used serially numbered, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition bias.
Selective reporting (reporting bias) Low risk No reporting bias.
Other bias High risk Stopped the study “when the plot of data
indicated one treatment superior to the
other”
Also states that “there were no significant
differences between the two groups in re-
gard to age, marital status, race, parity,
weeks of gestation, or cervical dilation at
the start of treatment, but the data is not
shown”
bpm: beats per minute
IM: intramuscular
IV: intravenous
RDS: respiratory distress syndrome
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Waltman 1969 This study is not a randomized controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Ethanol versus placebo/control




participants Statistical method Effect size
1 Birth < 48 hours after trial entry 1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.43, 2.00]
1.1 Women with intact
membranes
1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.43, 2.00]
1.2 Women with ruptured
membranes
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Women without specified
membrane status
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Perinatal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.1 Women with intact
membranes
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Women with ruptured
membranes
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Women without specified
membrane status
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Neonatal mortality 1 35 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.31, 3.58]
3.1 Women with intact
membranes
1 35 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.31, 3.58]
3.2 Women with ruptured
membranes
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Women without specified
membrane status
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Preterm birth < 37 weeks 1 35 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.72, 2.31]
5 Preterm birth < 34 weeks 1 35 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.69, 4.16]
6 Number of days delivery delayed 1 35 Mean Difference (IV, Fixed, 95% CI) -3.43 [-22.74, 15.
88]
7 Maternal adverse events (overall) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Maternal adverse events
(required stopping or changing
drug)
1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Respiratory distress syndrome 1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.27, 2.64]
10 Birthweight < 2500 g 1 35 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.81, 2.46]
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Comparison 2. Ethanol versus other tocolytic drug




participants Statistical method Effect size
1 Birth < 48 hours after trial entry 2 130 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.53, 2.37]
1.1 Women with intact
membranes
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Women with ruptured
membranes
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Women without specified
membrane status
2 130 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.53, 2.37]
2 Perinatal mortality 6 698 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.78, 1.84]
2.1 Women with intact
membranes
2 210 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.40, 2.05]
2.2 Women with ruptured
membranes
1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [0.52, 7.30]
2.3 Women without specified
membrane status
4 456 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.73, 2.19]
3 Neonatal mortality 8 1238 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.02, 2.02]
3.1 Women with intact
membranes
3 303 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.49, 2.11]
3.2 Women with ruptured
membranes
1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [0.52, 7.30]
3.3 Women without specified
membrane status
5 903 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [1.03, 2.35]
4 Preterm birth < 37 weeks 4 741 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.86, 1.36]
5 Preterm birth < 34 weeks 2 599 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [1.11, 2.19]
6 Number of days delivery delayed 5 585 Mean Difference (IV, Random, 95% CI) -2.51 [-11.11, 6.09]
7 Maternal adverse events (overall) 4 350 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.46, 2.11]
8 Maternal adverse events
(required stopping or changing
drug)
3 214 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.06, 0.97]
9 Respiratory distress syndrome 3 823 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [1.33, 2.33]
10 Birthweight < 2500 g 5 834 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [1.09, 1.54]
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Analysis 1.1. Comparison 1 Ethanol versus placebo/control, Outcome 1 Birth < 48 hours after trial entry.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 1 Birth < 48 hours after trial entry
Study or subgroup Ethanol Placebo/control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with intact membranes
Watring 1976 7/17 8/18 100.0 % 0.93 [ 0.43, 2.00 ]
Subtotal (95% CI) 17 18 100.0 % 0.93 [ 0.43, 2.00 ]
Total events: 7 (Ethanol), 8 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
2 Women with ruptured membranes
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Ethanol), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Women without specified membrane status
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Ethanol), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 17 18 100.0 % 0.93 [ 0.43, 2.00 ]
Total events: 7 (Ethanol), 8 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Ethanol versus placebo/control, Outcome 3 Neonatal mortality.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 3 Neonatal mortality
Study or subgroup Ethanol Placebo/control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with intact membranes
Watring 1976 4/17 4/18 100.0 % 1.06 [ 0.31, 3.58 ]
Subtotal (95% CI) 17 18 100.0 % 1.06 [ 0.31, 3.58 ]
Total events: 4 (Ethanol), 4 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 Women with ruptured membranes
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Ethanol), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Women without specified membrane status
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Ethanol), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 17 18 100.0 % 1.06 [ 0.31, 3.58 ]
Total events: 4 (Ethanol), 4 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.4. Comparison 1 Ethanol versus placebo/control, Outcome 4 Preterm birth < 37 weeks.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 4 Preterm birth < 37 weeks
Study or subgroup Ethanol Placebo/control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Watring 1976 11/17 9/18 100.0 % 1.29 [ 0.72, 2.31 ]
Total (95% CI) 17 18 100.0 % 1.29 [ 0.72, 2.31 ]
Total events: 11 (Ethanol), 9 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.5. Comparison 1 Ethanol versus placebo/control, Outcome 5 Preterm birth < 34 weeks.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 5 Preterm birth < 34 weeks
Study or subgroup Ethanol Placebo/control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Watring 1976 8/17 5/18 100.0 % 1.69 [ 0.69, 4.16 ]
Total (95% CI) 17 18 100.0 % 1.69 [ 0.69, 4.16 ]
Total events: 8 (Ethanol), 5 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Ethanol versus placebo/control, Outcome 6 Number of days delivery delayed.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 6 Number of days delivery delayed





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Watring 1976 17 20.29 (28.53) 18 23.72 (29.76) 100.0 % -3.43 [ -22.74, 15.88 ]
Total (95% CI) 17 18 100.0 % -3.43 [ -22.74, 15.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.8. Comparison 1 Ethanol versus placebo/control, Outcome 8 Maternal adverse events (required
stopping or changing drug).
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 8 Maternal adverse events (required stopping or changing drug)
Study or subgroup Ethanol Placebo/control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zlatnik 1972 0/21 0/21 Not estimable
Total (95% CI) 21 21 Not estimable
Total events: 0 (Ethanol), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Ethanol versus placebo/control, Outcome 9 Respiratory distress syndrome.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 9 Respiratory distress syndrome
Study or subgroup Ethanol Placebo/control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Watring 1976 4/17 5/18 100.0 % 0.85 [ 0.27, 2.64 ]
Total (95% CI) 17 18 100.0 % 0.85 [ 0.27, 2.64 ]
Total events: 4 (Ethanol), 5 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Ethanol versus placebo/control, Outcome 10 Birthweight < 2500 g.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 1 Ethanol versus placebo/control
Outcome: 10 Birthweight < 2500 g
Study or subgroup Ethanol Placebo/control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Watring 1976 12/17 9/18 100.0 % 1.41 [ 0.81, 2.46 ]
Total (95% CI) 17 18 100.0 % 1.41 [ 0.81, 2.46 ]
Total events: 12 (Ethanol), 9 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Ethanol versus other tocolytic drug, Outcome 1 Birth < 48 hours after trial
entry.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 1 Birth < 48 hours after trial entry








1 Women with intact membranes
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Ethanol), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Women with ruptured membranes
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Ethanol), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Women without specified membrane status
Sims 1978 20/46 22/42 62.3 % 0.83 [ 0.54, 1.29 ]
Spearing 1979 10/22 5/20 37.7 % 1.82 [ 0.75, 4.41 ]
Subtotal (95% CI) 68 62 100.0 % 1.12 [ 0.53, 2.37 ]
Total events: 30 (Ethanol), 27 (Other tocolytic)
Heterogeneity: Tau2 = 0.19; Chi2 = 2.47, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 68 62 100.0 % 1.12 [ 0.53, 2.37 ]
Total events: 30 (Ethanol), 27 (Other tocolytic)
Heterogeneity: Tau2 = 0.19; Chi2 = 2.47, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Ethanol versus other tocolytic drug, Outcome 2 Perinatal mortality.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 2 Perinatal mortality
Study or subgroup Ethanol Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with intact membranes
Caritis 1982 3/30 8/31 23.3 % 0.39 [ 0.11, 1.32 ]
Lauersen 1977 7/76 3/73 9.1 % 2.24 [ 0.60, 8.34 ]
Subtotal (95% CI) 106 104 32.4 % 0.91 [ 0.40, 2.05 ]
Total events: 10 (Ethanol), 11 (Other tocolytic)
Heterogeneity: Chi2 = 3.66, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Women with ruptured membranes
Caritis 1982 4/13 3/19 7.2 % 1.95 [ 0.52, 7.30 ]
Subtotal (95% CI) 13 19 7.2 % 1.95 [ 0.52, 7.30 ]
Total events: 4 (Ethanol), 3 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
3 Women without specified membrane status
Boyd 1978 3/50 4/55 11.3 % 0.83 [ 0.19, 3.51 ]
Forster 1987 (Part II) 13/105 9/118 25.1 % 1.62 [ 0.72, 3.64 ]
Reynolds 1978 4/42 6/42 17.8 % 0.67 [ 0.20, 2.19 ]
Spearing 1979 5/23 2/21 6.2 % 2.28 [ 0.49, 10.54 ]
Subtotal (95% CI) 220 236 60.4 % 1.26 [ 0.73, 2.19 ]
Total events: 25 (Ethanol), 21 (Other tocolytic)
Heterogeneity: Chi2 = 2.38, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 339 359 100.0 % 1.20 [ 0.78, 1.84 ]
Total events: 39 (Ethanol), 35 (Other tocolytic)
Heterogeneity: Chi2 = 7.05, df = 6 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 1.00, df = 2 (P = 0.61), I2 =0.0%
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Analysis 2.3. Comparison 2 Ethanol versus other tocolytic drug, Outcome 3 Neonatal mortality.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 3 Neonatal mortality
Study or subgroup Ethanol Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with intact membranes
Caritis 1982 2/30 6/31 11.9 % 0.34 [ 0.08, 1.57 ]
Castren 1975 5/50 4/43 8.7 % 1.08 [ 0.31, 3.75 ]
Lauersen 1977 7/76 3/73 6.2 % 2.24 [ 0.60, 8.34 ]
Subtotal (95% CI) 156 147 26.7 % 1.02 [ 0.49, 2.11 ]
Total events: 14 (Ethanol), 13 (Other tocolytic)
Heterogeneity: Chi2 = 3.35, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Women with ruptured membranes
Caritis 1982 4/13 3/19 4.9 % 1.95 [ 0.52, 7.30 ]
Subtotal (95% CI) 13 19 4.9 % 1.95 [ 0.52, 7.30 ]
Total events: 4 (Ethanol), 3 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
3 Women without specified membrane status
Forster 1987 (Part II) 12/105 9/118 17.1 % 1.50 [ 0.66, 3.41 ]
Forster 1987 (Part III) 22/222 17/242 32.8 % 1.41 [ 0.77, 2.59 ]
Reynolds 1978 3/42 4/42 8.1 % 0.75 [ 0.18, 3.15 ]
Sims 1978 10/46 4/42 8.4 % 2.28 [ 0.77, 6.73 ]
Spearing 1979 5/23 1/21 2.1 % 4.57 [ 0.58, 35.96 ]
Subtotal (95% CI) 438 465 68.4 % 1.56 [ 1.03, 2.35 ]
Total events: 52 (Ethanol), 35 (Other tocolytic)
Heterogeneity: Chi2 = 2.63, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
Total (95% CI) 607 631 100.0 % 1.43 [ 1.02, 2.02 ]
Total events: 70 (Ethanol), 51 (Other tocolytic)
Heterogeneity: Chi2 = 6.96, df = 8 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.040)
Test for subgroup differences: Chi2 = 1.21, df = 2 (P = 0.55), I2 =0.0%
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Analysis 2.4. Comparison 2 Ethanol versus other tocolytic drug, Outcome 4 Preterm birth < 37 weeks.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 4 Preterm birth < 37 weeks








Boyd 1978 34/48 37/48 28.7 % 0.92 [ 0.72, 1.17 ]
Castren 1975 22/50 10/43 10.2 % 1.89 [ 1.01, 3.54 ]
Forster 1987 (Part III) 130/222 118/242 33.7 % 1.20 [ 1.01, 1.42 ]
Sims 1978 32/46 32/42 27.4 % 0.91 [ 0.71, 1.18 ]
Total (95% CI) 366 375 100.0 % 1.08 [ 0.86, 1.36 ]
Total events: 218 (Ethanol), 197 (Other tocolytic)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.81, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Ethanol versus other tocolytic drug, Outcome 5 Preterm birth < 34 weeks.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 5 Preterm birth < 34 weeks
Study or subgroup Ethanol Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forster 1987 (Part III) 48/222 36/242 77.6 % 1.45 [ 0.98, 2.15 ]
Lauersen 1977 19/67 10/68 22.4 % 1.93 [ 0.97, 3.83 ]
Total (95% CI) 289 310 100.0 % 1.56 [ 1.11, 2.19 ]
Total events: 67 (Ethanol), 46 (Other tocolytic)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [ethanol] Favours [other tocolytic]
46Ethanol for preventing preterm birth in threatened preterm labor (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.6. Comparison 2 Ethanol versus other tocolytic drug, Outcome 6 Number of days delivery
delayed.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 6 Number of days delivery delayed





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Boyd 1978 48 18.8 (3.4) 48 15.2 (3.4) 20.9 % 3.60 [ 2.24, 4.96 ]
Caritis 1982 28 10 (3.2) 28 15 (3.7) 20.8 % -5.00 [ -6.81, -3.19 ]
Forster 1987 (Part II) 105 21.5 (3.3) 105 19.9 (3.3) 21.0 % 1.60 [ 0.71, 2.49 ]
Lauersen 1977 67 27.6 (3.1) 68 44 (3.9) 21.0 % -16.40 [ -17.59, -15.21 ]
Sims 1978 46 20.4 (24) 42 15 (24.5) 16.3 % 5.40 [ -4.75, 15.55 ]
Total (95% CI) 294 291 100.0 % -2.51 [ -11.11, 6.09 ]
Heterogeneity: Tau2 = 91.57; Chi2 = 688.23, df = 4 (P<0.00001); I2 =99%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Ethanol versus other tocolytic drug, Outcome 7 Maternal adverse events
(overall).
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 7 Maternal adverse events (overall)








Caritis 1982 32/40 13/45 26.6 % 2.77 [ 1.71, 4.49 ]
Castren 1975 5/50 9/43 19.5 % 0.48 [ 0.17, 1.32 ]
Reynolds 1978 32/42 26/42 28.6 % 1.23 [ 0.92, 1.65 ]
Sims 1978 11/46 22/42 25.3 % 0.46 [ 0.25, 0.82 ]
Total (95% CI) 178 172 100.0 % 0.99 [ 0.46, 2.11 ]
Total events: 80 (Ethanol), 70 (Other tocolytic)
Heterogeneity: Tau2 = 0.50; Chi2 = 25.22, df = 3 (P = 0.00001); I2 =88%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Ethanol versus other tocolytic drug, Outcome 8 Maternal adverse events
(required stopping or changing drug).
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 8 Maternal adverse events (required stopping or changing drug)
Study or subgroup Ethanol Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Reynolds 1978 0/42 3/42 35.8 % 0.14 [ 0.01, 2.68 ]
Sims 1978 1/46 5/42 53.5 % 0.18 [ 0.02, 1.50 ]
Spearing 1979 1/22 1/20 10.7 % 0.91 [ 0.06, 13.59 ]
Total (95% CI) 110 104 100.0 % 0.25 [ 0.06, 0.97 ]
Total events: 2 (Ethanol), 9 (Other tocolytic)
Heterogeneity: Chi2 = 1.11, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Ethanol versus other tocolytic drug, Outcome 9 Respiratory distress syndrome.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 9 Respiratory distress syndrome
Study or subgroup Ethanol Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forster 1987 (Part II) 32/105 20/105 32.5 % 1.60 [ 0.98, 2.61 ]
Forster 1987 (Part III) 59/222 37/242 57.5 % 1.74 [ 1.20, 2.51 ]
Lauersen 1977 15/76 6/73 9.9 % 2.40 [ 0.99, 5.85 ]
Total (95% CI) 403 420 100.0 % 1.76 [ 1.33, 2.33 ]
Total events: 106 (Ethanol), 63 (Other tocolytic)
Heterogeneity: Chi2 = 0.62, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.96 (P = 0.000074)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Ethanol versus other tocolytic drug, Outcome 10 Birthweight < 2500 g.
Review: Ethanol for preventing preterm birth in threatened preterm labor
Comparison: 2 Ethanol versus other tocolytic drug
Outcome: 10 Birthweight < 2500 g
Study or subgroup Ethanol Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Castren 1975 15/50 6/43 4.7 % 2.15 [ 0.91, 5.05 ]
Forster 1987 (Part III) 102/222 91/242 62.9 % 1.22 [ 0.98, 1.52 ]
Lauersen 1977 44/76 28/73 20.6 % 1.51 [ 1.07, 2.14 ]
Reynolds 1978 4/42 6/42 4.3 % 0.67 [ 0.20, 2.19 ]
Spearing 1979 13/23 10/21 7.5 % 1.19 [ 0.67, 2.11 ]
Total (95% CI) 413 421 100.0 % 1.30 [ 1.09, 1.54 ]
Total events: 178 (Ethanol), 141 (Other tocolytic)
Heterogeneity: Chi2 = 3.66, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
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